Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

0.6364 +0.0296 (+4.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 Next >
Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'
Via Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark... 
Via Benzinga
PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
Nektar Therapeutics (NASDAQ:NKTR) brought in sales totaling $21.59 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 75.97%, resulting in a loss of $159.07... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
Expert Ratings for Nektar Therapeutics
Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Recap: Nektar Therapeutics Q2 Earnings
Nektar Therapeutics (NASDAQ:NKTR) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
Via Benzinga
Expert Ratings for Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical... 
Via Benzinga
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.... 
Via Benzinga
Why Nektar Shares Are Down Almost 35%
Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Upgrades 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion.... 
Via Benzinga
Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Best Performers Since 3/14 Pivot
Early last week, the US equity market pivoted, gaining 1%+ for four consecutive days between last Tuesday and last Friday. Sentiment has shifted amongst the investing community for the time being. 
Via Talk Markets
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.